Ewing Sarcoma - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 326
Inquire Before Buying

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ewing Sarcoma - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ewing Sarcoma - Overview 7
Ewing Sarcoma - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Ewing Sarcoma - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Ewing Sarcoma - Companies Involved in Therapeutics Development 28
Amgen Inc 28
AntiCancer Inc 28
Astellas Pharma Inc 28
Bristol-Myers Squibb Co 29
Cebiotex SL 29
Celgene Corp 30
Celldex Therapeutics Inc 30
Eisai Co Ltd 31
EntreChem SL 31
Exelixis Inc 32
Gradalis Inc 32
Incyte Corp 33
Ipsen SA 33
MacroGenics Inc 34
MediaPharma SRL 34
Merck & Co Inc 34
Merrimack Pharmaceuticals Inc 35
NantKwest Inc 35
Novartis AG 36
Oncomatryx Biopharma SL 36
Oncternal Therapeutics Inc 37
Pfizer Inc 37
Pharma Mar SA 38
Tarveda Therapeutics Inc 38
Tesaro Inc 39
Ewing Sarcoma - Drug Profiles 40
12-B80 - Drug Profile 40
aldoxorubicin hydrochloride - Drug Profile 41
axitinib - Drug Profile 59
Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile 65
cabozantinib s-malate - Drug Profile 66
CEB-01 - Drug Profile 88
Cellular Immunotherapy 2 for Oncology - Drug Profile 89
Cellular Immunotherapy for Oncology - Drug Profile 91
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 93
Celyvir - Drug Profile 94
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 95
EC-8042 - Drug Profile 96
EC-8105 - Drug Profile 98
enoblituzumab - Drug Profile 99
everolimus - Drug Profile 102
ganitumab - Drug Profile 114
gemogenovatucel-T - Drug Profile 117
INCB-59872 - Drug Profile 122
ipilimumab + nivolumab - Drug Profile 123
irinotecan hydrochloride - Drug Profile 133
istiratumab - Drug Profile 145
JS-K - Drug Profile 148
KITSG-3227 - Drug Profile 149
KTN-0182A - Drug Profile 150
lenvatinib mesylate - Drug Profile 152
linsitinib - Drug Profile 171
lurbinectedin - Drug Profile 174
Monoclonal Antibody Conjugates for Ewing Sarcoma - Drug Profile 185
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 186
MPTEM-1ADC - Drug Profile 187
niraparib - Drug Profile 188
NV-101 - Drug Profile 197
NV-103 - Drug Profile 198
OMTX-503 - Drug Profile 199
OMTX-703 - Drug Profile 200
ONC-206 - Drug Profile 201
ONCase-PEG - Drug Profile 202
paclitaxel albumin bound - Drug Profile 203
pazopanib hydrochloride - Drug Profile 216
pembrolizumab - Drug Profile 225
PEN-866 - Drug Profile 294
RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile 297
sirolimus albumin-bound - Drug Profile 298
Small Molecules for Ewing Sarcoma - Drug Profile 300
SP-2509 - Drug Profile 301
SP-2577 - Drug Profile 302
talazoparib - Drug Profile 303
TK-216 - Drug Profile 310
Ewing Sarcoma - Dormant Projects 312
Ewing Sarcoma - Discontinued Products 313
Ewing Sarcoma - Product Development Milestones 314
Featured News & Press Releases 314
Appendix 322
Methodology 322
Coverage 322
Secondary Research 322
Primary Research 322
Expert Panel Validation 322
Contact Us 322
Disclaimer 323

List of Tables

Number of Products under Development for Ewing Sarcoma, H2 2017 11
Number of Products under Development by Companies, H2 2017 13
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Universities/Institutes, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Universities/Institutes, H2 2017 19
Number of Products by Stage and Target, H2 2017 21
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 22
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 23
Number of Products by Stage and Mechanism of Action, H2 2017 25
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 26
Number of Products by Stage and Route of Administration, H2 2017 28
Number of Products by Stage and Molecule Type, H2 2017 30
Ewing Sarcoma - Pipeline by Amgen Inc, H2 2017 31
Ewing Sarcoma - Pipeline by AntiCancer Inc, H2 2017 31
Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H2 2017 32
Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 32
Ewing Sarcoma - Pipeline by Cebiotex SL, H2 2017 33
Ewing Sarcoma - Pipeline by Celgene Corp, H2 2017 33
Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017 34
Ewing Sarcoma - Pipeline by Eisai Co Ltd, H2 2017 34
Ewing Sarcoma - Pipeline by EntreChem SL, H2 2017 35
Ewing Sarcoma - Pipeline by Exelixis Inc, H2 2017 35
Ewing Sarcoma - Pipeline by Gradalis Inc, H2 2017 35
Ewing Sarcoma - Pipeline by Incyte Corp, H2 2017 36
Ewing Sarcoma - Pipeline by Ipsen SA, H2 2017 36
Ewing Sarcoma - Pipeline by MacroGenics Inc, H2 2017 37
Ewing Sarcoma - Pipeline by MediaPharma SRL, H2 2017 37
Ewing Sarcoma - Pipeline by Merck & Co Inc, H2 2017 38
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 38
Ewing Sarcoma - Pipeline by NantKwest Inc, H2 2017 39
Ewing Sarcoma - Pipeline by Novartis AG, H2 2017 39
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H2 2017 40
Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H2 2017 40
Ewing Sarcoma - Pipeline by Pfizer Inc, H2 2017 41
Ewing Sarcoma - Pipeline by Pharma Mar SA, H2 2017 41
Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2017 41
Ewing Sarcoma - Pipeline by Tesaro Inc, H2 2017 42
Ewing Sarcoma - Dormant Projects, H2 2017 315
Ewing Sarcoma - Discontinued Products, H2 2017 316

List of Figures

Number of Products under Development for Ewing Sarcoma, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 15
Number of Products by Top 10 Targets, H2 2017 20
Number of Products by Stage and Top 10 Targets, H2 2017 20
Number of Products by Top 10 Mechanism of Actions, H2 2017 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 24
Number of Products by Routes of Administration, H2 2017 27
Number of Products by Stage and Routes of Administration, H2 2017 27
Number of Products by Molecule Types, H2 2017 29
Number of Products by Stage and Molecule Types, H2 2017 29

  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 27-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect. Cancer stem cells (CSCs) are cancer cells tha......
  • Pancreatic Cancer - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 2509
    Pancreatic Cancer - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may ......
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2000 Onwards        Pages: 853
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss ......
  • Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 1759
    Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells wit......
  • Global Non-small Cell Lung Cancer Therapeutics Sales Market Report 2018
    Published: 18-Jun-2018        Price: US 4000 Onwards        Pages: 105
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer othe......
  • Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2018
    Published: 18-Jun-2018        Price: US 2900 Onwards        Pages: 94
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Status and Forecast 2025
    Published: 13-Jun-2018        Price: US 3300 Onwards        Pages: 104
    This report studies the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by companies, region, type and end-use industry. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumo......
  • 2018-2023 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report (Status and Outlook)
    Published: 06-Jun-2018        Price: US 4660 Onwards        Pages: 153
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market for 2018-2023. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs ......
  • Global Cancer Gene Therapy Market Professional Survey Report 2018
    Published: 05-Jun-2018        Price: US 3500 Onwards        Pages: 120
    This report studies the global Cancer Gene Therapy market status and forecast, categorizes the global Cancer Gene Therapy market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Cancer Gene Therapy market is valued at xx million US$ in 2017 and is expected to reach xx milli......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs